Cancer News and Research

Latest Cancer News and Research

First human study to measure effects of BPA on male reproductive system

High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Emory researchers present public health research findings at American Public Health Association meeting

Emory University Rollins School of Public Health researchers will present Nov. 11 on a range of topics at the American Public Health Association's annual meeting in Philadelphia, including a study that found reduced absenteeism among employees participating in a large-scale worksite wellness program.

11 Nov 2009

World's smallest gastrointestinal videoscope with four-way angulation and NBI

Olympus today introduced the world's smallest gastrointestinal videoscope to offer four-way angulation and Narrow Band Imaging™ (NBI) to detect upper gastrointestinal abnormalities. The super-slim scope is 5.5 mm in diameter at the distal end, as well as the insertion tube, and offers exceptional insertion capability to enhance patient comfort. The scope also features NBI, Olympus' proprietary imaging technology that filters white light to consist of specific wavelength bands enabling enhanced observation of microvessels and subtle changes on the mucosa.

From Evident Corporation - Life Sciences 11 Nov 2009

Minimally invasive surgical techniques as effective as traditional open surgery in treating rectal cancers

Laparoscopic surgery has been used in the treatment of intestinal disorders for close to 20 years, but its benefits have only recently begun to be extended to people with rectal cancer. In a prospective study of 103 patients who underwent straightforward or "hand-assisted" laparoscopic surgery for rectal cancer, a team of colon and rectal surgeons at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has shown that the minimally invasive approach can be as effective as traditional open surgery in treating rectal cancers.

11 Nov 2009

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Poniard Pharmaceuticals, Inc. today announced that the Company will present updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC) and final results from its Phase 1 cardiac safety trial.

11 Nov 2009

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

NIDA supports new drug detection research

Every time a person snorts cocaine, it doesn't just go to his or her head: It also provokes a response in the immune system, creating special biomolecules that may serve as a permanent record of each exposure.

11 Nov 2009

Hoag Memorial Hospital Presbyterian to implement complete SIS Solution at Hoag Hospital Irvine

Hoag Memorial Hospital Presbyterian in Newport Beach, CA has expanded its partnership with Surgical Information Systems (SIS) by adding anesthesia, business intelligence and tissue management capabilities to its existing system, and by extending the SIS Solution to Hoag Hospital Irvine, which is scheduled to open in 2010.

11 Nov 2009

Sprycel holds hope for treating Src dependent ovarian cancer

The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Common myths about sun exposure, sunscreen and vitamin D

When it comes to vitamin D, consumers are bombarded with mixed messages about the best source for this essential nutrient. While some may argue that small doses of intentional sun exposure are safe, dermatologists point out that the risk of developing skin cancer from ultraviolet (UV) radiation far outweighs the benefit of stimulating vitamin D production - particularly when enriched foods and supplements are safe and effective sources of this vitamin.

11 Nov 2009

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. The findings will be published online on Nov. 10, 2009 in the Journal of the National Cancer Institute (ahead of the Dec. 2, 2009 print edition).

11 Nov 2009

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Microbix Biosystems Inc. today announced that KINLYTIC (urokinase for injection) has been approved in Canada for marketing and export. Health Canada's issuance of a Drug Identification Number for KINLYTIC gives Microbix the opportunity to market the product in Canada and export the clot-busting therapy to markets worldwide.

11 Nov 2009

Potential new drug for lung cancer eliminates tumors in mice

A potential new drug for lung cancer has eliminated tumours in 50% of mice in a new study published today in the journal Cancer Research. In the animals, the drug also stopped lung cancer tumours from growing and becoming resistant to treatment. The authors of the research, from Imperial College London, are now planning to take the drug into clinical trials, to establish whether it could offer hope to patients with an inoperable form of lung cancer.

11 Nov 2009

Children with autism have slower pupil responses to light change: Study

Autism affects 1 in 150 children today, making it more common than childhood cancer, juvenile diabetes and pediatric AIDS combined. Despite its widespread effect, autism is not well understood and there are no objective medical tests to diagnose it. Recently, University of Missouri researchers have developed a pupil response test that is 92.5 percent accurate in separating children with autism from those with typical development. In the study, MU scientists found that children with autism have slower pupil responses to light change.

11 Nov 2009

No protection for 90% of Africans from secondhand smoke

As African nations are poised to undergo the highest increase in the rate of tobacco use among developing countries, nearly 90 percent of people on the continent remain without meaningful protection from secondhand smoke, according to a new report released at a regional cancer conference today.

10 Nov 2009

Cancer News and Research

Latest Cancer News and Research

First human study to measure effects of BPA on male reproductive system

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Emory researchers present public health research findings at American Public Health Association meeting

World's smallest gastrointestinal videoscope with four-way angulation and NBI

Minimally invasive surgical techniques as effective as traditional open surgery in treating rectal cancers

Poniard Pharmaceuticals to present picoplatin Phase 2 trial data at the AACR-NCI -EORTC conference

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

NIDA supports new drug detection research

Hoag Memorial Hospital Presbyterian to implement complete SIS Solution at Hoag Hospital Irvine

Sprycel holds hope for treating Src dependent ovarian cancer

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Common myths about sun exposure, sunscreen and vitamin D

Anemia-reducing medications linked to deep vein thrombosis in cancer patients

Microbix Biosystems receives Health Canada's marketing and export approval for KINLYTIC

Potential new drug for lung cancer eliminates tumors in mice

Children with autism have slower pupil responses to light change: Study

No protection for 90% of Africans from secondhand smoke

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in